Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Categories (click each to see list of all clinical trials associated with that category): Thoracic (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Sharma, Bhavina
Contact Information:
Kimberly Shields
kimberly.shields@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06074588?term=NCT06074588&rank=1
Summary
Primary Objective:
To compare MK-2870 to chemotherapy with respect to PFS per RECIST 1.1 as assessed by BICR in NSCLC with EGFR
mutations. -To compare MK-2870 to chemotherapy with respect to OS in NSCLC with EGFR mutations.
Secondary Objectives:
-To compare MK-2870 to chemotherapy with respect to PFS per RECIST 1.1 as assessed by BICR in all participants
with NSCLC. -To compare MK-2870 to chemotherapy with respect to OS in all participants with NSCLC. -To compare
ORR per RECIST 1.1 based on BICR of MK-2870 to chemotherapy in NSCLC with EGFR mutations. -To compare ORR
per RECIST 1.1 based on BICR of MK-2870 to chemotherapy in all participants with NSCLC. -To evaluate DOR of
MK-2870 versus chemotherapy in NSCLC with EGFR mutations and in all participants with
NSCLC. -To evaluate the mean change from baseline in global health status/QoL, dyspnea, cough, and chest pain for
MK-2870 versus chemotherapy in NSCLC with EGFR mutations and in all participants with NSCLC. -To evaluate the
time to deterioration in global health status/QoL, dyspnea, cough, and chest pain for MK-2870 versus chemotherapy
in NSCLC with EGFR mutations and in all participants with NSCLC. -To evaluate the safety and tolerability of MK-2870